Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Carparts.Com Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Carparts.Com Inc trades at $6 (market cap $49.97M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 89.9× Carparts.Com Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | PRTS | |
|---|---|---|
Market Cap | $4.49B | $49.97M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $11.40 |
52-Week Low | $20.06 | $3.88 |
Enterprise Value | $3.69B | $64.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CarParts.com (PRTS) trades at $6.14, down 0.65% on the day, following a recent 10:1 reverse stock split that helped it regain Nasdaq compliance. The stock shows a bearish technical signal with negative cash flow and net losses, though it has beaten earnings estimates for three consecutive quarters. Recent developments include a new $25 million credit facility and the launch of a co-branded Mastercard, signaling efforts to stabilize operations and enhance customer financing options.
Despite persistent losses and negative cash flow, PRTS maintains a low P/S ratio of 0.07 and has analyst support with 60% buy ratings. The primary risk is sustained profitability challenges amid declining revenue, but cost discipline and new financial tools may provide a path to recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
